"Antibody Affinity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
| Descriptor ID |
D000915
|
| MeSH Number(s) |
G12.040 G12.122.125
|
| Concept/Terms |
Antibody Affinity- Antibody Affinity
- Affinity, Antibody
- Affinities, Antibody
- Antibody Affinities
Antibody Avidity- Antibody Avidity
- Antibody Avidities
- Avidities, Antibody
- Avidity, Antibody
|
Below are MeSH descriptors whose meaning is more general than "Antibody Affinity".
Below are MeSH descriptors whose meaning is more specific than "Antibody Affinity".
This graph shows the total number of publications written about "Antibody Affinity" by people in this website by year, and whether "Antibody Affinity" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2005 | 1 | 1 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 2 | 2 |
| 2015 | 1 | 1 | 2 |
| 2016 | 2 | 0 | 2 |
| 2017 | 9 | 14 | 23 |
| 2018 | 7 | 9 | 16 |
| 2019 | 1 | 1 | 2 |
| 2020 | 3 | 13 | 16 |
| 2021 | 5 | 11 | 16 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibody Affinity" by people in Profiles.
-
Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Avidity Maturation and Association with Disease Severity. Clin Infect Dis. 2021 11 02; 73(9):e3095-e3097.
-
TOP-Plus Is a Versatile Biosensor Platform for Monitoring SARS-CoV-2 Antibody Durability. Clin Chem. 2021 09 01; 67(9):1249-1258.
-
Incomplete IgG avidity maturation after seasonal coronavirus infections. J Med Virol. 2022 01; 94(1):186-196.
-
The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants. Cell Rep. 2021 09 07; 36(10):109679.
-
Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. Immunity. 2021 08 10; 54(8):1853-1868.e7.
-
HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine. Front Immunol. 2021; 12:734689.
-
Production of scFv, Fab, and IgG of CR3022 Antibodies Against SARS-CoV-2 Using Silkworm-Baculovirus Expression System. Mol Biotechnol. 2021 Dec; 63(12):1223-1234.
-
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape. Nature. 2021 09; 597(7874):97-102.
-
Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
-
Prospects of Neutralizing Nanobodies Against SARS-CoV-2. Front Immunol. 2021; 12:690742.